Mergers & Acquisitions (M&A)

Photo
19.09.2025 • NewsPharma

Roche to Acquire 89bio in $3.5 Billion Deal

Acquisition supports Roche’s strategy as it enhances the company’s portfolio in cardiovascular, renal, and metabolic diseases (CVRM) and offers optionality for future combination development.

Photo
10.09.2025 • News

Symeres Acquires DGr Pharma

CRDMO Symeres has acquired DGr Pharma, expanding its capabilities with DGr Pharma’s regulatory and consultancy expertise to provide more comprehensive drug development services.

Photo
28.08.2025 • NewsStrategy

IMCD to Acquire Tillmanns

IMCD, a partner for the distribution and formulation of speciality chemicals and ingredients, has signed an agreement to acquire 100% of the shares in Tillmanns.

Photo
21.07.2025 • News

Harke Acquires Swedish Vendico

Harke Group, based in Mülheim an der Ruhr, Germany, acquired the Swedish Vendico Group, comprising Vendico Chemical, Inventicon, and Omni International.

Photo
08.07.2025 • News

Bio-Rad Acquires Stilla Technologies

Bio-Rad Laboratories, a life science research and clinical diagnostics company, has completed the acquisition of Stilla Technologies, a developer of digital PCR (dPCR) systems.

Photo
02.07.2025 • News

BASF Completes Acquisition of DOMO Chemicals' Shares in Alsachimie JV

BASF has acquired DOMO Chemicals' 49% stake in the Alsachimie joint venture and is now the sole owner of the production company for essential precursors of polyamide (PA) 6.6, including KA oil, adipic acid and hexamethylenediamine adipate (AH salt) in Chalampé, France. The parties have agreed not to disclose financial details of the transaction.

Photo
02.06.2025 • News

BASF to Acquire Shares in Alsachimie

BASF and DOMO Chemicals have signed an agreement giving BASF the right to acquire DOMO Chemicals' 49% stake in the Alsachimie joint venture, in which BASF currently holds 51%.

2001 more articles

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.